Foundayo (Orforglipron) Side Effects: Clinical Rates, Relief Tips & Safety Rules

Key Takeaways

60–69% of Foundayo trial participants reported at least one digestive symptom (nausea ~1 in 3, constipation 20–27%, diarrhea 20–27%), with only ~4% rated severe.
Around 90% of patients completed treatment, as symptoms peak during early 30-day dose escalations and settle over time.
Important precautions: use backup barrier contraception for 30 days after starting and after each dose increase if taking oral contraceptive pills, and inform surgical/anesthesia teams before procedures.

Following regulatory authorization of Foundayo (orforglipron) — the once-daily non-peptide oral GLP-1 tablet — clinical trial data from ATTAIN-1 and ATTAIN-2 give a clear picture of what patients actually experience (1–3). Roughly 90% of trial participants stayed on treatment, though 60%–69% noticed at least one gastrointestinal symptom, with only ~4% classed as severe (3,5).

Managing the big three digestive symptoms

Nausea (~33% of users): Eat smaller meals slowly, avoid fried or rich foods during dose step-ups, stay upright after eating, and sip ginger/peppermint tea or water steadily (3–6).
Constipation (20%–27%): Increase fruits, vegetables, and whole-grain fiber gradually, drink plenty of water, and take short daily walks (4,5).
Diarrhea (20%–27%): Prioritize steady fluid and electrolyte hydration and choose simple, bland low-fat meals until settled (5).

Three key safety rules before starting Foundayo

Oral contraception backup: Because delayed gastric emptying and GI symptoms affect pill absorption, add barrier contraception for 30 days after starting and for 30 days after every dose increase; stop before pregnancy (3).
Thyroid & pancreas history: Contraindicated in personal/family history of medullary thyroid carcinoma (MTC) or MEN2; seek urgent care for severe persistent upper abdominal pain radiating to the back (pancreatitis) or right-upper-quadrant pain/jaundice (gallbladder) (3,6).
Anesthesia & surgery: Always notify your surgical and anesthesia team before any sedated procedure, as GLP-1s slow stomach emptying even after standard fasting (3).

Explore current oral and injectable weight management options with our clinicians today.

References

Wharton S, Aronne LJ, et al. Orforglipron for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025.
Horn DB, Ryan DH, et al. Orforglipron in Type 2 Diabetes & Obesity (ATTAIN-2)02165-8/abstract). Lancet. 2025.
Eli Lilly. FOUNDAYO (orforglipron) Prescribing Information. FDA; 2026.

Medical Editorial Review: Reviewed by the Amble Clinical Editorial Team. This article is for educational purposes only and does not replace an individualized consultation with a licensed healthcare professional.